Yes. Current U.S. labeling includes Ozempic tablets containing semaglutide. The tablet is taken daily, while Ozempic injection is taken weekly. They have separate dosing and administration instructions. The oral label specifically warns that Ozempic tablets and Rybelsus tablets are not interchangeable milligram for milligram. Current oral prescribing information, sections 2–3
That answer may differ from older articles describing Ozempic as injection-only. The important next question is whether the exact product, indication, and directions on your prescription match the current label, rather than whether a seller calls something an “Ozempic pill.”
Which product is an Ozempic tablet?
The current DailyMed record identifies Ozempic as an oral semaglutide tablet under NDA 213051. Its product listing gives April 27, 2026 as the marketing start date. The prescribing information, revised January 2026, covers both Rybelsus and Ozempic tablets. A marketing record does not establish local pharmacy stock, an individual's coverage, or a personal price. Those must be checked separately. DailyMed product information and prescribing information
| Product named on the label | Active ingredient and form | Schedule described in its label | Important distinction |
|---|---|---|---|
| Ozempic tablets | Oral semaglutide | Daily | Tablet-specific strengths and administration rules |
| Rybelsus tablets | Oral semaglutide | Daily | Different strengths; not an equal-milligram substitution for Ozempic tablets |
| Ozempic injection | Injectable semaglutide | Weekly | Injection-specific dose, device, and clinical instructions |
Sharing an active ingredient does not make every version interchangeable. The oral formulation contains salcaprozate sodium, commonly called SNAC, an absorption enhancer. That ingredient also matters for the lactation advice discussed below. Oral label, sections 2, 8.2 and 11
What are Ozempic tablets approved to treat?
The oral label includes use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes. It also includes reducing major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events. These indications identify a particular disease and patient population. They are not a general approval for anyone seeking weight loss. Oral label, section 1
It is also important to distinguish the tablet label from the Ozempic injection label. For example, the injection has a specified kidney-outcomes indication in adults with type 2 diabetes and chronic kidney disease. Do not assume that every indication, study result, or dosing instruction from one formulation applies to the other. Injection label, section 1
Your clinician can explain which labeled use applies and what evidence supports the prescribed formulation. If the discussion is about weight management, ask for the exact product and indication rather than assuming every semaglutide product has the same approval.
How does taking the tablet differ from an injection?
The oral prescribing information directs patients to take one tablet in the morning on an empty stomach with water only, using no more than four ounces. Swallow it whole; do not split, crush, chew, or dissolve it. Wait at least 30 minutes before eating, drinking, or taking other oral medicines. A missed tablet is skipped, with the next dose taken the following day. Oral label, section 2.1
These are meaningful practical differences from a weekly injection. If you take morning medicines or have an unpredictable breakfast routine, ask the pharmacist how the prescribed schedule should work. Do not rearrange other important medicines based solely on an article.
The label provides product-specific starting and escalation instructions, but a general comparison should not be used to choose your own dose. In particular, a larger milligram number does not necessarily mean a stronger or equivalent dose across tablet formulations. Your prescription and the correct product label should guide the plan.
What safety details deserve attention?
Ozempic tablets carry a boxed warning about thyroid C-cell tumors observed in rodents; the relevance to humans is unknown. The label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or MEN 2 and in people with a relevant serious hypersensitivity reaction. Other important warnings include pancreatitis, diabetic retinopathy complications, hypoglycemia with certain diabetes medicines, dehydration-related kidney injury, severe gastrointestinal effects, gallbladder disease, and pulmonary aspiration during anesthesia or deep sedation. Oral label, sections 4–5
Tell the prescriber about your medication list, medical history, pregnancy plans, breastfeeding, and scheduled procedures. The tablet label advises that breastfeeding is not recommended during treatment because SNAC or its metabolites enter human milk and potential infant accumulation is a concern. Evidence about injected semaglutide should not be used to override that tablet-specific advice. Oral label, section 8.2
A product-check worksheet before you fill a prescription
Use this to confirm what is actually being offered:
| Check | What to record or ask |
|---|---|
| Exact identity | Brand, active ingredient, tablet or injection, and prescribed strength |
| Source of the claim | The current official label for that exact product, not a screenshot of another formulation |
| Treatment purpose | The condition being treated and whether the proposed use is on-label or off-label |
| Daily routine | How the fasting interval, water amount, and other oral medicines fit together |
| Access | The dispensing pharmacy, actual stock, coverage decision, and written price |
| Follow-up | Who reviews response, adverse effects, and any future formulation change |
If an offer says “oral GLP-1,” “sublingual semaglutide,” or “custom semaglutide,” that wording alone does not establish that it is Ozempic tablets. Read the exact product identity. Our oral and sublingual GLP-1 guide explains those broader categories.
Related reading: Rybelsus and weight loss.
Educational information only. This article does not replace an individual medication decision with your care team. Sources checked October 24, 2026.
Frequently Asked Questions
Is an Ozempic pill the same as Rybelsus?
Both current tablet labels contain semaglutide, but the strengths differ and the prescribing information explicitly says they are not milligram-for-milligram substitutes. Any transition requires the correct product-specific prescribing instructions.
Can I replace my weekly injection with a tablet myself?
No. Do not infer an equivalent tablet dose from the injection dose. Ask the prescriber to confirm the intended formulation, transition instructions, and monitoring.
Are Ozempic tablets approved for weight loss?
The oral label reviewed here lists adult type 2 diabetes glycemic control and specified cardiovascular risk reduction. It does not list a general weight-management indication. A different product's approval cannot be transferred to this brand and formulation.
Does the label prove my pharmacy has it or my plan covers it?
No. A product listing, a pharmacy stock check, and an insurance claim answer different questions. Confirm each before relying on an offer or changing an existing treatment plan. For a related discussion, see Rybelsus and weight loss.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Rybelsus and Ozempic tablets: current prescribing information and product record · DailyMed, U.S. National Library of Medicine · accessed
- 2.Ozempic injection: current prescribing information · DailyMed, U.S. National Library of Medicine · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them